Roswell Park Comprehensive Cancer Center

A restrictive opioid prescription protocol of 3 days or less after hospital discharge appeared feasible among a cohort of patients who underwent surgery at a large cancer center, according to study results published in JAMA Oncology.

Joyce Ohm, PhD, has been named chair of cancer genetics and genomics at Roswell Park Comprehensive Cancer Center.

A chimeric antigen receptor T-cell therapy produced a response rate of 71% among patients with relapsed or refractory multiple myeloma, according to phase 1 study results published in The New England Journal of Medicine.

Glioblastoma, the most common primary brain cancer, is known to be highly aggressive and deadly.

American Society for Radiation Oncology has announced Howard Sandler, MD, FASTRO, as its new president-elect, along with several new officers elected to its board of directors, according to a press release.

Marco Davila, MD, PhD, has been appointed senior vice president and associate director for translational research at Roswell Park Comprehensive Cancer Center.

Erik Knudsen, PhD, has been appointed associate director of basic science research at Roswell Park Comprehensive Cancer Center.

Genetic variants of the UACA gene, a critical regulator of tumor suppressor Par-4, appeared associated with OS among patients who received anthracyclines and HER2-targeted therapy, according to a study published in NPJ Breast Cancer.

Sotorasib exhibited durable efficacy among certain adults with locally advanced or metastatic non-small cell lung cancer, according to study results presented at American Association for Cancer Research Annual Meeting.

For many in oncology, attending medical conferences is essential to stay up to speed on the latest treatment advances and research. But for one early-career oncologist, attending one meeting was also career changing.